Manufacturing Roundup – 1 April 2019
Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.
You may also be interested in...
Zydus Cadila has received a warning letter from the FDA for its Moraiya facility. The company has insisted that it will not affect the existing business in the US where it has filed over 330 ANDAs.
Alkem said it had a “mixed year”, registering growth in India and internationally despite setbacks that included a weak anti-infectives season and a recent Form 483 from the US Food and Drug Administration.
Sterling Pharma Solutions has acquired a US facility and Olon has bought a plant from Sandoz, while Normon is investing €100m in manufacturing expansions.